RxDoctor Payments Data

Paul Lavigne, MD

Interventional Cardiology · Norfolk, VANPI 1992935076

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Penumbra, Inc. at 40.0% of the total. Reporting peaked in 2020 at $5,645 and has fallen 87.2% since, to $721 in 2025.

$13,780in general payments, 2019–2025

Across 133 payments — averaging $103.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$6K
  • Abiomed$4K
  • Boston Scientific$1K
  • Medtronic$677
  • Philips North America LLC$626
  • Shockwave Medical, Inc$506
  • plus $1K from 10 others
$133,661in research payments, 2019–2025

Across 30 payments — averaging $4455.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$39K
  • Shockwave Medical, Inc$33K
  • Janssen Research & Development, LLC$27K
  • Philips North America LLC$18K
  • Boehringer Ingelheim International GmbH$17K
  • Abiomed$263
  • plus $19 from 1 others

What the payments were for

  • Speaking & faculty fees$4,80035%
  • Travel & lodging$3,01322%
  • Food & beverage$5,86343%
  • Other$1041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,780 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$246,997
Medicare patients
931
Services billed
2,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$29,571
XareltoRivaroxaban27$26,142
EntrestoSacubitril/Valsartan21$17,858
Atorvastatin Calcium106$1,156
Amlodipine Besylate98$1,015
Metoprolol Succinate66$918
Losartan Potassium59$744
Rosuvastatin Calcium34$696
Carvedilol57$572
Ezetimibe30$546
Isosorbide Mononitrate ErIsosorbide Mononitrate14$391
Hydrochlorothiazide43$253
Spironolactone31$244
ClopidogrelClopidogrel Bisulfate32$243
Warfarin Sodium14$241

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →